Clinical Trials Browser

Phase 3 × Urinary Bladder Neoplasms × avelumab × Clear all

NCT05092958 2026-05-13

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02603432 2024-03-27

JAVELIN Bladder 100

Phase 3 Completed

700 enrolled 35 charts 1 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms